Welcome to On The Drop, Mission Bio’s official podcast dedicated to bringing forth leading conversations in cancer research leveraging advances in single-cell multi-omics. Start listening below!
This week, we're excited to explore the origins of Women of Mission Bio Group (WOMO) and are delighted to speak with one of it's founders Samantha Mason, Mission Bio's Director of Software Products. Samantha founded WOMO as a safe space for women, by women, to come together from across the organization where they can openly discuss topics pertaining to women, network, and providing leadership guidance during times of adversity.
In this Researcher Spotlight Series, we speak with Linde Miles from the Memorial Sloan Kettering Cancer Center, New York. Linde has participated in the largest study ever to investigate the genetic roots of Leukemia at the single-cell level. Last October, she co-authored a paper in Nature titled "Single-cell mutation analysis of clonal evolution in myeloid malignancies".
In this Researcher Spotlight Series, we speak with Doug Marchuk and Daniel Snellings from the Duke University School of Medicine. Doug and Daniel's work centers on the genetics that underlies cardiovascular diseases. They recently published a paper in Nature entitled, PIK3CA and CCM Mutations Fuel Cavernomas Through a Cancer-Like Mechanism.
Last month, Mission Bio launched it’s PAD (Pharma Assay Development) solutions. In this weeks episode, Harsha Kavuri tackles some of the exciting benefits and capabilities PAD may be used in bringing effective therapies to cancer patients.
In this researcher spotlight series, we are honored to speak with Dr. Ross Levine from Memorial Sloan Kettering. Dr. Levine aims to better understand the genetic basis of myeloid malignancies and discusses his journey in hematological oncology and how using single-cell analysis has furthered advancements in his research.
In this episode, we chatted with Ilaria Iacobucci, PhD from the St. Jude Children’s Research Hospital about pairing single-cell analysis with CRISPR, women in science, and pandemic woes.